Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.79
Dollar change
+0.03
Percentage change
1.70
%
Index- P/E- EPS (ttm)-0.56 Insider Own24.75% Shs Outstand49.04M Perf Week-3.24%
Market Cap87.78M Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float36.90M Perf Month-24.15%
Income-27.03M PEG- EPS next Q-0.14 Inst Own18.32% Short Float4.05% Perf Quarter4.07%
Sales0.00M P/S- EPS this Y-1.79% Inst Trans-13.31% Short Ratio6.91 Perf Half Y21.77%
Book/sh0.79 P/B2.27 EPS next Y-26.32% ROA-47.51% Short Interest1.49M Perf Year175.38%
Cash/sh0.55 P/C3.23 EPS next 5Y- ROE-57.02% 52W Range0.61 - 4.19 Perf YTD1.70%
Dividend Est.- P/FCF- EPS past 5Y19.89% ROI-69.87% 52W High-57.28% Beta1.03
Dividend TTM- Quick Ratio4.07 Sales past 5Y0.00% Gross Margin- 52W Low194.89% ATR (14)0.15
Dividend Ex-Date- Current Ratio4.07 EPS Y/Y TTM36.41% Oper. Margin0.00% RSI (14)35.36 Volatility7.39% 7.87%
Employees28 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price5.25
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q35.63% Payout- Rel Volume0.74 Prev Close1.76
Sales Surprise- EPS Surprise-16.67% Sales Q/Q- EarningsMar 19 AMC Avg Volume216.31K Price1.79
SMA20-10.97% SMA50-14.46% SMA200-7.57% Trades Volume160,298 Change1.70%
Date Action Analyst Rating Change Price Target Change
Aug-18-23Initiated Oppenheimer Outperform $7
Dec-01-21Resumed Jefferies Buy $8
May-27-21Initiated Cantor Fitzgerald Overweight $10
Feb-10-21Downgrade Mizuho Buy → Neutral $7 → $4
Sep-12-19Initiated Mizuho Buy
May-29-19Initiated ROTH Capital Buy $6
Aug-24-17Upgrade Credit Suisse Underperform → Neutral
May-01-17Downgrade Credit Suisse Neutral → Underperform
Apr-18-16Initiated Guggenheim Buy
Apr-18-16Initiated Credit Suisse Outperform
Mar-22-24 12:00PM
Mar-21-24 09:48AM
Mar-20-24 06:32AM
Mar-19-24 04:08PM
04:02PM
04:02PM Loading…
Mar-13-24 04:02PM
Feb-12-24 09:22AM
08:30AM
Feb-08-24 04:05PM
Feb-06-24 04:05PM
Jan-23-24 05:00PM
Dec-11-23 12:00PM
Dec-09-23 12:00PM
Dec-07-23 09:40AM
Nov-21-23 09:40AM
11:56AM Loading…
Nov-08-23 11:56AM
08:43AM
Nov-07-23 04:32PM
04:01PM
Nov-02-23 09:15AM
Nov-01-23 07:31PM
Oct-31-23 04:02PM
Sep-06-23 04:05PM
Aug-30-23 10:01AM
Aug-08-23 04:35PM
04:01PM
Aug-01-23 08:30AM
Jul-06-23 12:59PM
Jun-29-23 07:00AM
Jun-15-23 07:00AM
08:10AM Loading…
Jun-04-23 08:10AM
May-31-23 08:30AM
08:11AM
May-26-23 09:40AM
May-17-23 09:00AM
May-12-23 10:04AM
May-10-23 04:06PM
May-08-23 04:11PM
04:01PM
Apr-24-23 08:38AM
Apr-20-23 09:00AM
Apr-17-23 09:00AM
Apr-03-23 08:30AM
Mar-30-23 06:08AM
Mar-28-23 04:02PM
Mar-21-23 04:05PM
Mar-14-23 04:35PM
Feb-21-23 02:34PM
09:51AM
07:00AM
Feb-02-23 05:41AM
Dec-12-22 10:00AM
Dec-05-22 08:30AM
Nov-14-22 08:30AM
Nov-03-22 04:05PM
09:52AM
Oct-27-22 04:05PM
Oct-25-22 04:05PM
Oct-14-22 09:55AM
Oct-04-22 01:15PM
Sep-27-22 08:51AM
Sep-26-22 04:05PM
Sep-06-22 04:05PM
Aug-26-22 06:13AM
Aug-11-22 12:00PM
Aug-08-22 04:05PM
Jul-28-22 04:05PM
Jul-21-22 04:05PM
May-10-22 07:30AM
May-07-22 09:43AM
May-05-22 04:05PM
Apr-26-22 07:30AM
Mar-19-22 08:06AM
Mar-10-22 04:05PM
Mar-03-22 04:30PM
Jan-13-22 06:30PM
Jan-01-22 07:43AM
Dec-13-21 09:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-02-21 04:05PM
09:00AM
Nov-01-21 04:05PM
Oct-27-21 04:05PM
Oct-25-21 07:30PM
Sep-29-21 07:11AM
Sep-28-21 02:30PM
Sep-27-21 10:08AM
Sep-24-21 03:54PM
Sep-22-21 03:45PM
07:35AM
06:00AM
06:00AM
Sep-20-21 08:14AM
04:58AM
Sep-17-21 12:28PM
11:45AM
07:31AM
Sep-16-21 11:03AM
Sep-15-21 11:40AM
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grais LindaDirectorMay 15 '23Buy2.4510,00024,50010,000May 16 04:54 PM